• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

以成年耳部皮肤全器官为模型研究血管畸形。

Whole mount of adult ear skin as a model to study vascular malformations.

机构信息

Biology Department, Utica University, Utica, New York, USA.

Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, New York, USA.

出版信息

Animal Model Exp Med. 2023 Aug;6(4):362-368. doi: 10.1002/ame2.12343.

DOI:10.1002/ame2.12343
PMID:37682010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10486327/
Abstract

BACKGROUND

Genetic analysis in human patients has linked mutations in PIK3CA, the catalytic subunit of PI-3'Kinase, to sporadic incidences of vascular malformations.

METHODS

We have developed a mouse model with inducible and endothelial-specific expression of PIK3CA , resulting in the development of vascular malformations. Systemic induction of this mutation in adult mice results in rapid lethality, limiting our ability to track and study these lesions; therefore, we developed a topical and local induction protocol using the active metabolite of tamoxifen, 4OH-T, on the ear skin of adults.

RESULTS

This approach allows us to successfully model the human disease in a mature and established vascular bed and track the development of vascular malformations. To validate the utility of this model, we applied a topical rapamycin ointment, as rapamycin is therapeutically beneficial to patients in clinical trials. We found that the induced ear lesions showed significant attenuation after treatment, which was easily quantified.

CONCLUSIONS

These data collectively provide evidence of a new model to study vascular malformations in adult tissues, which should be particularly useful in environments lacking specialized small-animal imaging facilities.

摘要

背景

在人类患者中进行的遗传分析将 PIK3CA(PI-3'激酶的催化亚基)的突变与散发性血管畸形联系起来。

方法

我们开发了一种具有可诱导和内皮特异性表达 PIK3CA 的小鼠模型,导致血管畸形的发展。在成年小鼠中全身性诱导这种突变会导致快速死亡,限制了我们追踪和研究这些病变的能力;因此,我们开发了一种使用他莫昔芬的活性代谢物 4OH-T 在成年耳朵皮肤进行局部诱导的方案。

结果

这种方法使我们能够在成熟和已建立的血管床上成功模拟人类疾病,并追踪血管畸形的发展。为了验证该模型的实用性,我们应用了局部雷帕霉素软膏,因为雷帕霉素在临床试验中对患者具有治疗益处。我们发现,诱导的耳部病变在治疗后明显减轻,这很容易量化。

结论

这些数据共同提供了一种在成年组织中研究血管畸形的新模型的证据,对于缺乏专门的小动物成像设施的环境尤其有用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8c3/10486327/ff22fde72662/AME2-6-362-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8c3/10486327/b7abbcc4ebf2/AME2-6-362-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8c3/10486327/1b50c2e3c67a/AME2-6-362-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8c3/10486327/33e3ad0ad0bf/AME2-6-362-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8c3/10486327/ff22fde72662/AME2-6-362-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8c3/10486327/b7abbcc4ebf2/AME2-6-362-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8c3/10486327/1b50c2e3c67a/AME2-6-362-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8c3/10486327/33e3ad0ad0bf/AME2-6-362-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8c3/10486327/ff22fde72662/AME2-6-362-g005.jpg

相似文献

1
Whole mount of adult ear skin as a model to study vascular malformations.以成年耳部皮肤全器官为模型研究血管畸形。
Animal Model Exp Med. 2023 Aug;6(4):362-368. doi: 10.1002/ame2.12343.
2
Targeted therapy for capillary-venous malformations.靶向治疗毛细血管静脉畸形。
Signal Transduct Target Ther. 2024 Jun 17;9(1):146. doi: 10.1038/s41392-024-01862-9.
3
Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.磷脂酰肌醇-3激酶催化亚基α(PIK3CA)的体细胞激活突变可导致小鼠和人类出现散发性静脉畸形。
Sci Transl Med. 2016 Mar 30;8(332):332ra43. doi: 10.1126/scitranslmed.aad9982.
4
Genetic landscape of common venous malformations in the head and neck.头颈部常见静脉畸形的遗传景观。
J Vasc Surg Venous Lymphat Disord. 2021 Jul;9(4):1007-1016.e7. doi: 10.1016/j.jvsv.2020.11.016. Epub 2020 Nov 26.
5
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.PI3K/mTOR 抑制促进由 PIK3CA 激活突变驱动的实验性血管畸形的消退。
Cell Death Dis. 2018 Jan 19;9(2):45. doi: 10.1038/s41419-017-0064-x.
6
The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.PI3K 相关血管畸形的发生发生在血管生成过程中,并可被 AKT 抑制剂 miransertib 所预防。
EMBO Mol Med. 2022 Jul 7;14(7):e15619. doi: 10.15252/emmm.202115619. Epub 2022 Jun 13.
7
PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).PIK3CA 突变与 mTOR 通路表达相关,但与纤维脂肪性血管异常(FAVA)的临床和病理特征无关。
Diagn Pathol. 2022 Jan 30;17(1):19. doi: 10.1186/s13000-022-01199-3.
8
A xenograft model for venous malformation.静脉畸形的异种移植模型。
Angiogenesis. 2018 Nov;21(4):725-735. doi: 10.1007/s10456-018-9624-7. Epub 2018 May 21.
9
Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.毛细血管淋巴管静脉畸形中淋巴管和血管内皮细胞表达组成性激活的 PIK3CA 突变。
Angiogenesis. 2020 Aug;23(3):425-442. doi: 10.1007/s10456-020-09722-0. Epub 2020 Apr 30.
10
CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.CD10 和 CD34 作为 PIK3CA 和 TEK 突变的血管畸形标志物。
Hum Pathol. 2020 May;99:98-106. doi: 10.1016/j.humpath.2020.04.001. Epub 2020 Apr 6.

本文引用的文献

1
The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.PI3K 相关血管畸形的发生发生在血管生成过程中,并可被 AKT 抑制剂 miransertib 所预防。
EMBO Mol Med. 2022 Jul 7;14(7):e15619. doi: 10.15252/emmm.202115619. Epub 2022 Jun 13.
2
Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.西罗莫司(雷帕霉素)治疗儿童慢血流畸形:PERFORMUS 试验的观察阶段随机临床试验。
JAMA Dermatol. 2021 Nov 1;157(11):1289-1298. doi: 10.1001/jamadermatol.2021.3459.
3
Vascular and Lymphatic Malformations: Perspectives From Human and Vertebrate Studies.
血管和淋巴管畸形:来自人类和脊椎动物研究的观点。
Circ Res. 2021 Jun 25;129(1):131-135. doi: 10.1161/CIRCRESAHA.121.319587. Epub 2021 Jun 24.
4
Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.西罗莫司治疗广泛和/或复杂慢血流血管畸形有效:单中心前瞻性 II 期研究。
Orphanet J Rare Dis. 2018 Oct 29;13(1):191. doi: 10.1186/s13023-018-0934-z.
5
Intravital imaging-based analysis tools for vessel identification and assessment of concurrent dynamic vascular events.基于活体成像的血管识别分析工具及其对并发动态血管事件的评估。
Nat Commun. 2018 Jul 16;9(1):2746. doi: 10.1038/s41467-018-04929-8.
6
PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations.PIK3CA 突变特异性定位于淋巴管畸形的淋巴管内皮细胞。
PLoS One. 2018 Jul 9;13(7):e0200343. doi: 10.1371/journal.pone.0200343. eCollection 2018.
7
Intravital Imaging of Human Melanoma Cells in the Mouse Ear Skin by Two-Photon Excitation Microscopy.通过双光子激发显微镜对小鼠耳部皮肤中的人黑色素瘤细胞进行活体成像。
Methods Mol Biol. 2018;1755:223-232. doi: 10.1007/978-1-4939-7724-6_15.
8
Whole-mount Confocal Microscopy for Adult Ear Skin: A Model System to Study Neuro-vascular Branching Morphogenesis and Immune Cell Distribution.成人耳部皮肤的整装共聚焦显微镜检查:一种用于研究神经血管分支形态发生和免疫细胞分布的模型系统。
J Vis Exp. 2018 Mar 29(133):57406. doi: 10.3791/57406.
9
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.PI3K/mTOR 抑制促进由 PIK3CA 激活突变驱动的实验性血管畸形的消退。
Cell Death Dis. 2018 Jan 19;9(2):45. doi: 10.1038/s41419-017-0064-x.
10
Reductions in brain pericytes are associated with arteriovenous malformation vascular instability.脑周细胞减少与动静脉畸形血管不稳定有关。
J Neurosurg. 2018 Dec 1;129(6):1464-1474. doi: 10.3171/2017.6.JNS17860. Epub 2018 Jan 5.